PD-L1 is a biomarker for chemotherapy in various cancers [45, 46], demonstrating that immune molecule-related biomarkers may be important guides for the application of chemotherapy in the future, and further indicating that the combination of immunotherapy and chemotherapy is expected to be a promising prospect for SCLC patients. Here, CD274 is linked to cancer.